AKBA

Akebia Therapeut

• TipRanks·3d ago

  Akebia Therapeutics Earnings Call: Vafseo Drives Transition

• TipRanks·05/09 01:21

  Akebia Therapeutics Balances Vafseo Momentum With Headwinds

• Seeking Alpha·05/07 19:52

  Akebia outlines Phase II FSGS study of up to ~60 patients as Vafseo reaches nearly 7,500 patients

• Seeking Alpha·05/07 16:35

  Akebia plunges 20% on muted Q1 print

• TipRanks·05/07 15:21

  Akebia reports Q1 EPS (3c), consensus 0c

• Seeking Alpha·05/07 11:14

  Akebia GAAP EPS of -$0.03 in-line, revenue of $53.5M beats by $1.83M

• Reuters·05/07 11:11

  Akebia Q1 revenue falls, net income misses analyst estimates on higher expenses

• PUBT·05/07 11:10

  Akebia Q1 FY26 turns to net loss of $9.1 million; revenue falls to $53.5 million

• Benzinga·05/07 11:05

  Akebia Therapeutics Q1 EPS $(0.03), Inline, Sales $53.544M Beat $51.668M Estimate

• Dow Jones·05/07 11:00

  Press Release: Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

• PUBT·05/04 20:13

  Akebia grants new hires options for 208,800 shares at $1.38 each

• Benzinga·05/04 12:10

  Akebia Therapeutics Announces Publication Of Post-Hoc Win Statistics Analysis Of All-Cause Mortality And Hospitalization From Its Global Phase 3 INNO2VATE Program In The Journal Of The American Society Of Nephrology

• PUBT·05/04 12:01

  Akebia win-statistics analysis shows vadadustat cuts death, hospitalization vs darbepoetin in dialysis CKD

• PUBT·04/30 20:35

  Akebia Therapeutics schedules quarterly results conference call

• NASDAQ·04/28 08:00

  New Strong Sell Stocks for April 28th